Vera Therapeutics, Inc. (VERA)
Nasdaq · Healthcare · Biotechnology
$29.83−1.94%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.1B
- 52-week range
- $23.05 – $56.05
- 52-week change
- −1.68%
- EPS (trailing)
- −$5.87
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$300M
- Diluted EPS
- −$4.66
- Free cash flow
- −$242M
From the company’s annual report on SEC EDGAR.
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Headquarters: Brisbane, United States · 361 employees · veratx.com